Do analysts rate LIMN or SKYE?

Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,177.71%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Which has higher earnings and valuation, LIMN or SKYE?

Skye Bioscience is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is LIMN or SKYE more profitable?

Liminatus Pharma's return on equity of 0.00% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Skye Bioscience N/A -217.27% -162.39%

Does the media refer more to LIMN or SKYE?

In the previous week, Liminatus Pharma had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.57 beat Liminatus Pharma's score of 0.88 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer LIMN or BRNS?

Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 497.01%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LIMN or BRNS more profitable?

Liminatus Pharma's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Barinthus Biotherapeutics N/A -63.83% -48.77%

Do analysts prefer SCYX or LIMN?

SCYNEXIS currently has a consensus price target of $24.00, indicating a potential upside of 389.60%. Given SCYNEXIS's stronger consensus rating and higher possible upside, equities research analysts plainly believe SCYNEXIS is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to SCYX or LIMN?

In the previous week, Liminatus Pharma had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.93 beat Liminatus Pharma's score of 0.88 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NRSN or LIMN?

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A

Is NRSN or LIMN more profitable?

Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Liminatus Pharma N/A N/A -299.79%

Do analysts recommend ALLR or LIMN?

Allarity Therapeutics presently has a consensus target price of $9.75, indicating a potential upside of 470.18%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allarity Therapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALLR or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Liminatus Pharma N/A N/A -299.79%

Does the media favor ALLR or LIMN?

In the previous week, Liminatus Pharma had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for Allarity Therapeutics. Liminatus Pharma's average media sentiment score of 0.88 beat Allarity Therapeutics' score of 0.30 indicating that Liminatus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Liminatus Pharma (LIMN) Competitors

$0.15 +0.00 (+0.86%)

As of 02:27 PM Eastern

Compare

LIMN vs. SKYE, BRNS, SCYX, NRSN, and ALLR

Should you buy Liminatus Pharma stock or one of its competitors? MarketBeat compares Liminatus Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Liminatus Pharma include Skye Bioscience (SKYE), Barinthus Biotherapeutics (BRNS), SCYNEXIS (SCYX), NeuroSense Therapeutics (NRSN), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry.

How does Liminatus Pharma compare to Skye Bioscience?

Liminatus Pharma (NASDAQ:LIMN) and Skye Bioscience (NASDAQ:SKYE) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Skye Bioscience is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

In the previous week, Liminatus Pharma had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.57 beat Liminatus Pharma's score of 0.88 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liminatus Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

21.1% of Skye Bioscience shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Liminatus Pharma's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Skye Bioscience	N/A	-217.27%	-162.39%

Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,177.71%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Skye Bioscience beats Liminatus Pharma on 8 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Barinthus Biotherapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 497.01%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Liminatus Pharma's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 10.7% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Liminatus Pharma has higher earnings, but lower revenue than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Barinthus Biotherapeutics	$14.97M	1.83	-$66.43M	-$1.29	N/A

In the previous week, Liminatus Pharma had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for Barinthus Biotherapeutics. Liminatus Pharma's average media sentiment score of 0.88 beat Barinthus Biotherapeutics' score of 0.43 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Positive
Barinthus Biotherapeutics	Neutral

Summary

Barinthus Biotherapeutics beats Liminatus Pharma on 7 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

54.4% of SCYNEXIS shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SCYNEXIS currently has a consensus price target of $24.00, indicating a potential upside of 389.60%. Given SCYNEXIS's stronger consensus rating and higher possible upside, equities research analysts plainly believe SCYNEXIS is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SCYNEXIS has higher revenue and earnings than Liminatus Pharma. SCYNEXIS is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	1.33	-$8.61M	-$3.84	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

Liminatus Pharma has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Liminatus Pharma's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Liminatus Pharma	N/A	N/A	-299.79%

In the previous week, Liminatus Pharma had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.93 beat Liminatus Pharma's score of 0.88 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liminatus Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SCYNEXIS beats Liminatus Pharma on 9 of the 14 factors compared between the two stocks.

How does Liminatus Pharma compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

NeuroSense Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 986.96%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NeuroSense Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Liminatus Pharma	N/A	N/A	-299.79%

1.0% of NeuroSense Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Liminatus Pharma had 2 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.87 beat Liminatus Pharma's score of 0.88 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Very Positive
Liminatus Pharma	Positive

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

Summary

NeuroSense Therapeutics beats Liminatus Pharma on 8 of the 12 factors compared between the two stocks.

How does Liminatus Pharma compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Liminatus Pharma had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for Allarity Therapeutics. Liminatus Pharma's average media sentiment score of 0.88 beat Allarity Therapeutics' score of 0.30 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liminatus Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liminatus Pharma has lower revenue, but higher earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	85.02	-$11.23M	-$0.72	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

Liminatus Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Liminatus Pharma	N/A	N/A	-299.79%

Allarity Therapeutics presently has a consensus target price of $9.75, indicating a potential upside of 470.18%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allarity Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.5% of Allarity Therapeutics shares are held by institutional investors. 0.1% of Allarity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Allarity Therapeutics beats Liminatus Pharma on 7 of the 13 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIMN vs. The Competition

Export

Metric	Liminatus Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$6.82M	$435.55M	$4.35B	$12.48B
Dividend Yield	N/A	N/A	7.42%	5.22%
P/E Ratio	-0.35	N/A	21.82	24.39
Price / Sales	N/A	330.51	174.63	116.29
Price / Cash	N/A	N/A	58.60	57.13
Price / Book	-0.43	2.75	30.96	6.74
Net Income	-$10.21M	-$81.71M	$109.80M	$337.03M
7 Day Performance	-15.00%	-5.43%	-0.48%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	N/A	N/A	15.50%	34.29%

Liminatus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIMN Liminatus Pharma	0.8808 of 5 stars	$0.15 +0.9%	N/A	N/A	$6.82M	N/A	N/A	N/A	News Coverage Short Interest Decrease Gap Down
SKYE Skye Bioscience	2.2702 of 5 stars	$0.78 +1.3%	$9.80 +1,156.4%	-66.7%	$27.41M	N/A	N/A	11	Positive News
BRNS Barinthus Biotherapeutics	2.0685 of 5 stars	$0.67 -4.4%	$4.00 +497.0%	-35.1%	$27.37M	$14.97M	N/A	107	Short Interest Increase Gap Down
SCYX SCYNEXIS	2.1532 of 5 stars	$4.89 +4.6%	$24.00 +391.3%	-33.9%	$27.25M	$20.60M	N/A	60
NRSN NeuroSense Therapeutics	3.5465 of 5 stars	$0.80 +2.5%	$8.50 +962.5%	-55.1%	$26.05M	N/A	N/A	10	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIMN) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liminatus Pharma (LIMN) Competitors

LIMN vs. SKYE, BRNS, SCYX, NRSN, and ALLR

How does Liminatus Pharma compare to Skye Bioscience?

Summary

How does Liminatus Pharma compare to Barinthus Biotherapeutics?

Summary

How does Liminatus Pharma compare to SCYNEXIS?

Summary

How does Liminatus Pharma compare to NeuroSense Therapeutics?

Summary

How does Liminatus Pharma compare to Allarity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liminatus Pharma (LIMN) Competitors

LIMN vs. SKYE, BRNS, SCYX, NRSN, and ALLR

How does Liminatus Pharma compare to Skye Bioscience?

Which has higher earnings and valuation, LIMN or SKYE?

Does the media refer more to LIMN or SKYE?

Do institutionals & insiders believe in LIMN or SKYE?

Is LIMN or SKYE more profitable?

Do analysts rate LIMN or SKYE?

Summary

How does Liminatus Pharma compare to Barinthus Biotherapeutics?

Do analysts prefer LIMN or BRNS?

Is LIMN or BRNS more profitable?

Do insiders and institutionals believe in LIMN or BRNS?

Which has preferable earnings and valuation, LIMN or BRNS?

Does the media prefer LIMN or BRNS?

Summary

How does Liminatus Pharma compare to SCYNEXIS?

Do institutionals and insiders believe in SCYX or LIMN?

Do analysts prefer SCYX or LIMN?

Which has higher earnings & valuation, SCYX or LIMN?

Is SCYX or LIMN more profitable?

Does the media refer more to SCYX or LIMN?

Summary

How does Liminatus Pharma compare to NeuroSense Therapeutics?

Do analysts prefer NRSN or LIMN?

Is NRSN or LIMN more profitable?

Do institutionals and insiders believe in NRSN or LIMN?

Does the media refer more to NRSN or LIMN?

Which has higher earnings & valuation, NRSN or LIMN?

Summary

How does Liminatus Pharma compare to Allarity Therapeutics?

Does the media favor ALLR or LIMN?

Which has stronger valuation & earnings, ALLR or LIMN?

Is ALLR or LIMN more profitable?

Do analysts recommend ALLR or LIMN?

Do insiders and institutionals believe in ALLR or LIMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools